SAR of 3,4-Dihydropyrido[3,2-d]pyrimidone p38 inhibitors
- 3 October 2003
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 13 (22), 3979-3982
- https://doi.org/10.1016/j.bmcl.2003.08.059
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- p38MAP kinase inhibitors. part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffoldBioorganic & Medicinal Chemistry Letters, 2003
- Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinaseBioorganic & Medicinal Chemistry Letters, 2003
- Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activityBioorganic & Medicinal Chemistry Letters, 2001
- RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potencyBioorganic & Medicinal Chemistry Letters, 2001
- Role of p38 Mitogen-Activated Protein Kinase in Rhinovirus-Induced Cytokine Production by Bronchial Epithelial CellsPublished by The American Association of Immunologists ,2000
- Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritisArthritis & Rheumatism, 2000
- Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein KinaseJournal of Medicinal Chemistry, 1999
- Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinaseBioorganic & Medicinal Chemistry, 1997
- A protein kinase involved in the regulation of inflammatory cytokine biosynthesisNature, 1994
- A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian CellsScience, 1994